表紙
市場調査レポート

Targovax ASの製品パイプライン分析

Targovax AS - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321962
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Targovax ASの製品パイプライン分析 Targovax AS - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 32 Pages
概要

Targovax ASはノルウェーに本社をおく製薬企業で、腫瘍に対するワクチン開発に注力しています。能動免疫療法用の癌ワクチンの開発や、アンメットメディカルニーズを伴う幅広い適応症に対応した抗がん用免疫医薬品をパイプラインに有しています。

当レポートでは、Targovax AS における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Targovax AS の基本情報

  • Targovax AS の概要
  • 主要情報
  • 企業情報

Targovax AS :R&Dの概要

  • 主な治療範囲

Targovax AS :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Targovax AS :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Targovax AS :薬剤プロファイル

  • TG-01
  • TG-02
  • TG-03

Targovax AS :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Targovax AS :最新のパイプライン情報

Targovax AS :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07929CDB

Summary

Global Markets Direct's, 'Targovax AS - Product Pipeline Review - 2015', provides an overview of the Targovax AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Targovax AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Targovax AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Targovax AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Targovax AS's pipeline products

Reasons to buy

  • Evaluate Targovax AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Targovax AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Targovax AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Targovax AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Targovax AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Targovax AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Targovax AS Snapshot
    • Targovax AS Overview
    • Key Information
    • Key Facts
  • Targovax AS - Research and Development Overview
    • Key Therapeutic Areas
  • Targovax AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Targovax AS - Pipeline Products Glance
    • Targovax AS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Targovax AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Targovax AS - Drug Profiles
    • TG-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-802
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-902
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Targovax AS - Pipeline Analysis
    • Targovax AS - Pipeline Products by Target
    • Targovax AS - Pipeline Products by Route of Administration
    • Targovax AS - Pipeline Products by Molecule Type
    • Targovax AS - Pipeline Products by Mechanism of Action
  • Targovax AS - Recent Pipeline Updates
  • Targovax AS - Dormant Projects
  • Targovax AS - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Targovax AS, Key Information
  • Targovax AS, Key Facts
  • Targovax AS - Pipeline by Indication, 2015
  • Targovax AS - Pipeline by Stage of Development, 2015
  • Targovax AS - Monotherapy Products in Pipeline, 2015
  • Targovax AS - Phase II, 2015
  • Targovax AS - Phase I, 2015
  • Targovax AS - Preclinical, 2015
  • Targovax AS - Discovery, 2015
  • Targovax AS - Pipeline by Target, 2015
  • Targovax AS - Pipeline by Route of Administration, 2015
  • Targovax AS - Pipeline by Molecule Type, 2015
  • Targovax AS - Pipeline Products by Mechanism of Action, 2015
  • Targovax AS - Recent Pipeline Updates, 2015
  • Targovax AS - Dormant Developmental Projects,2015
  • Targovax AS, Subsidiaries

List of Figures

  • Targovax AS - Pipeline by Top 10 Indication, 2015
  • Targovax AS - Pipeline by Stage of Development, 2015
  • Targovax AS - Monotherapy Products in Pipeline, 2015
  • Targovax AS - Pipeline by Top 10 Target, 2015
  • Targovax AS - Pipeline by Top 10 Route of Administration, 2015
  • Targovax AS - Pipeline by Top 10 Molecule Type, 2015
  • Targovax AS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top